Phase 1b/2 Clinical Trial – Crohn’s Disease
Tiziana Life Sci PLC (TILS.L) Phase 1b/2 Clinical Trial – Crohn’s Disease
Recommended Cash Offer for LiDCO Group Plc (LID.L) Masimo LHC Limited
RECOMMENDED CASH OFFER for LIDCO GROUP PLC (“LIDCO”) by MASIMO LHC LIMITED (“MASIMO”)
Tiziana Life Sci PLC (TILS.L) Initiation of Clinical Trial for COVID-19 Patients
Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Tiziana Life Sci (TILS.L) Exercise of options, Issue of Equity, PDMR Dealing
London, New York, 26 October 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation
TIZIANA LIFE SCI PLC (TILS.L) Result of General Meeting
At the General Meeting of the Company held at 11.00 a.m. on 2 October 2020, both of the resolutions were duly passed.
TIZIANA LIFE SCI PLC (TILS.L) Interview – Bloomberg International
Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report
Tiziana Life Sci PLC (TILS.L) Publication of Research Note
London, New York, 21 September 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), is pleased to note the publication of a new analyst
Tiziana Life Sci PLC (TILS.L) Clinical Study with Nasally Administered Foralumab
Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil
Tiziana Life Sci PLC (TILS.L) Demerger of StemPrintER and Distribution in Specie
Demerger of StemPrintER and Distribution in SpecieProposed capital reduction and notice of General Meeting
TPI provides its latest research note on N4 Pharma plc (N4P.L).
N4P has announced the appointment of Ardena Holding NV (‘Ardena’) as its contract development and manufacturing organisation (‘CDMO’) partner for the technology transfer and upscaling manufacture of Nuvec®, the Group’s unique silica nanoparticle
N4 Pharma PLC (N4P.L) Technology Transfer and Manufacturing Contract
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing, a novel delivery system for cancer treatments and vaccines, announces that it has appointed the API and Nanomedicines business unit
